Acute renal failure (ARF) is a common complication following allogeneic hematopoietic SCT (HSCT). Numerous conditions may be associated with early ARF including pre-existing kidney dysfunction, hypertension, TBI, sepsis, sinusoidal occlusion syndrome, dehydration, acute GVHD, nephrotoxic drugs and microangiopathic syndromes, which include both thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. The incidence of microangiopathic syndromes ranges from 2 to 21% after allogeneic HSCT, and identified primary risk factors include TBI and use of calcineurin inhibitors. Clinically, thrombotic thrombocytopenic purpura tends to occur early, often within the first 90 days of transplant, whereas hemolytic uremic syndrome seems to occur much later.
1 Direct malignant infiltration of the kidneys at diagnosis of acute leukemia is an extremely rare cause of early ARF and has been described in a few children only. 2, 3 Calcineurin inhibitor toxicity remains among the most common causes of late ARF. CsA and tacrolimus are both potent vasoconstrictors of the glomerulus afferent arteriole and known to cause various damages, including arteriolar injury, glomerular sclerosis and interstitial fibrosis as well as diffuse expansion of the mesangial matrix. An unusual cause of late ARF includes radiation nephritis, which may present acutely, 6-12 months after irradiation or late, 2-5 years later. Rarely, late ARF has been associated with membranous nephropathy, a manifestation of chronic GVHD. Diffuse proliferative glomerulonephritis, antineutrophil cytoplasmic Ab-related glomerulo-nephritis, focal segmental glomerulosclerosis and Ig A nephropathy have been described as well in association with chronic GVHD. 4 We describe herein the first case of an adult patient presenting with late ARF because of bilateral kidney involvement by ALL several months after allogeneic HSCT.
A 46-year-old man with ALL, L2 subtype, underwent a 6/6 HLA-matched related donor allogeneic HSCT in CR following induction chemotherapy with Cancer and Leukemia Group B (CALGB) protocol 9111. The conditioning regimen consisted of CY (120 mg/kg) and TBI (12 Gy); GVHD prophylaxis regimen used was short course MTX and CsA. Successful engraftment was achieved after infusion of G-CSF-mobilized stem cells. Marrow and peripheral blood chimerism studies performed using short variable tandem repeats by PCR assay (GenePrint STR Systems, Promega, Madison, WI, USA) revealed 100% donor cells on several occasions after transplant. On day þ 125, the patient developed de novo extensive chronic GVHD with mouth, eyes and skin involvement, for which he was initially treated with prednisone and tacrolimus. Mycophenolate mofetil was subsequently added due to suboptimal response. Twentyeight months after transplant, while on tapering immunosuppressors (prednisone 20 mg daily, mycophenolate mofetil 500 mg daily, tacrolimus 3 mg twice daily every other day), the patient presented with rapidly progressive severe low back pain. Physical examination was unremarkable except for new onset severe hypertension (192 systolic; 111 diastolic) and bilateral lower leg edema. Renal failure (creatinine of 196 mmol/l) was noted for the first time after HSCT and persisted despite immediate withdrawal of tacrolimus. Blood counts, blood smear and other routine biochemistry exams were normal. BM aspirate and biopsy were consistent with complete morphologic remission. Both bacterial and viral urine cultures were negative. Surprisingly, abdominal ultrasound showed bilaterally enlarged kidneys (left 20 Â 20 cm, right 21 Â 21 cm; Figure 1 ). The abdominal computer tomography scan revealed isolated bilateral nephromegaly without evidence of pathologic adenopathy, infiltrate or compression. Renal circulation was normal by angiographic magnetic resonance imaging (angio-MRI). Finally, a percutaneous right kidney needle biopsy revealed a diffuse tubulo-interstitial infiltrate by cells with scarce cytoplasm, oval nuclei and thin chromatin without nucleoli that were positive for CD79a, terminal deoxynucleotidyl transferase and CD10 by immunochemistry (Figure 2 ). These findings were identical to those of the initial diagnosis. After careful re-examination of admission BM biopsy, two small aggregates of CD10 þ positive cells were also identified by immunohistochemistry, consistent with early marrow relapse of ALL. The patient received re-induction therapy with DNR, VCR and prednisone but died 10 days later from septic shock. Autopsy, however limited to both kidneys only, confirmed extensive leukemic infiltrate.
Extra-medullary relapse of ALL following allogeneic HSCT in adult patients is well described, the central nervous system and testes being the most frequently reported sites of recurrence. 5 It is usually associated with a very poor prognosis, most patients being unable to tolerate aggressive systemic chemotherapy due to cumulative toxicities of previously administered regimens. Reasons for extra-medullary relapse of leukemia remain unclear; however, adhesion molecules seem to have a critical role in accumulation of lymphoid blasts as expression of unusual surface markers by leukemic cells in extra-medullary sites has been reported. 6 Another hypothesis is that recurrence occurs in sites protected from systemic chemotherapy by biological blood barriers such as the central nervous system or distinct growth conditions such as a lower temperature in testes. Similar to sanctuary sites for chemotherapy, these anatomic sites could be sanctuaries for the GVL effect. The kidney tubulointerstitium may represent another immune privileged site, not sufficiently accessible to cytotoxic T lymphocytes. Letter to the Editor
